Pfizer Covid-19 vaccine generates robust antibody response in children, without serious safety issues, company says
Pfizer and its partner BioNTech said Monday that they would file for authorization of their Covid-19 vaccine for use in children after clinical trial results showed encouraging antibody levels in volunteers and side effects similar to those in teens and young adults.
The pediatric study, in children ages 5 to 11, is the first to disclose results in young children.
